BioArctic ABBRCTF 84 Net Margin % is 48.54% as of Mar. 2026, which is 130% above its 10-year median of 21.09. GuruFocus rates BRCTF with a GF Score™ of 84/100 and a GF Value™ of $49.29 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 947 Biotechnology companies, BioArctic AB ranks better than 86.38% on this metric.
Net margin is calculated as Net Income divided by its Revenue. BioArctic AB's Net Income for the
three
months ended in Mar. 2026 was $22.8 Mil. BioArctic AB's Revenue for the
three
months ended in Mar. 2026 was $47.0 Mil. Therefore, BioArctic AB's net margin for the quarter that ended in Mar. 2026 was 48.54%.
The historical rank and industry rank for BioArctic AB's Net Margin % or its related term are showing as below:
BRCTF'
s Net Margin % Range Over the Past 10 Years
Min: -517.54 Med: 21.09 Max: 54.52
Current: 18.59
BRCTF's Net Margin % is ranked better than 86.38% of 947
companies
in the Biotechnology industry
Industry Median: -89.33
vs BRCTF: 18.59
BioArctic AB (OTCPK:BRCTF) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
BioArctic AB Net Margin % Related Terms
BioArctic AB Net Margin % Historical Data
* Premium members only.
The historical data trend for BioArctic AB's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BRCTF vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, BioArctic AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioArctic AB Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioArctic AB's Net Margin % distribution charts can be found below:
* The bar in red indicates where BioArctic AB's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioArctic AB (BRCTF) has a Net Margin % of 48.54% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on BioArctic AB and its competitors. This is 130% above median its historical median of 21.09. According to the industry distribution chart, BioArctic AB ranks #129 out of 947 companies in the Biotechnology industry, placing it in the top 13.6%.
Is BioArctic AB's Net Margin % too high?
BioArctic AB's current Net Margin % of 48.54% is 130% above median its 10-year median of 21.09. Based on the distribution chart, BioArctic AB ranks #129 out of 947 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioArctic AB has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioArctic AB's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioArctic AB ranks #129 out of 947 companies for Net Margin %. This places BioArctic AB in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on BioArctic AB and its competitors. BioArctic AB's current Net Margin % is 48.54%, which is 130% above median its own 10-year median of 21.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioArctic AB stock overvalued right now?
Based on GuruFocus' analysis, BioArctic AB (BRCTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $49.29, compared to a current price of $35.00 — trading 29% below its estimated fair value. The current Net Margin % is 48.54%, which is 130% above median its 10-year median of 21.09. BioArctic AB's overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For BioArctic AB (BRCTF), the current Net Margin % is 48.54% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioArctic AB (BRCTF) Overvalued in 2026?
Based on GuruFocus' analysis, BioArctic AB stock appears to be undervalued.
The current stock price of $35.00 is trading 29% below its estimated GF Value™ of $49.29.
GuruFocus considers BioArctic AB to be Modestly Undervalued.
Key valuation signals for BRCTF:
Net Margin %: 48.54% (130% above median its 10-year median of 21.09)
GF Value™: $49.29 vs. price of $35.00 (29% below fair value)
No single metric tells the full story. See the BRCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. Geographically, it derives a majority of its revenue from North America.
84GF Score
Get the complete analysis for BRCTF
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BRCTF has been successfully added to your 
